Laboratorios Farmaceuticos Rovi, SA (ES:ROVI)
BME:ROVI
Want to see ES:ROVI full AI Analyst Report?
ROVI Stock Chart & Stats
€64.90
-€1.60(-2.48%)
At close: 4:00 PM EST
€64.90
-€1.60(-2.48%)
Day’s Range― - ―
52-Week Range€50.90 - €86.70
Previous CloseN/A
Volume14.43K
Average Volume (3M)126.41K
Market Cap
€2.96B
Enterprise Value€3.08B
Total Cash (Recent Filing)€97.39M
Total Debt (Recent Filing)€114.44M
Price to Earnings (P/E)108.9
Beta0.67
Next Earnings
Jul 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.5%
Share Statistics
EPS (TTM)2.57
Shares Outstanding51,235,764
10 Day Avg. Volume117,821
30 Day Avg. Volume126,405
Financial Highlights & Ratios
PEG Ratio7.72
Price to Book (P/B)4.89
Price to Sales (P/S)4.37
P/FCF Ratio27.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€73.60Price Target Upside13.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.66
Revenue Forecast (FY)€773.87M
Bulls Say, Bears Say
Bulls Say
Balance-sheet StrengthLow leverage and a conservative balance sheet materially increase financial flexibility over the medium term. With modest net debt and meaningful equity, ROVI can fund CDMO capacity adds, pipeline R&D and dividend policy without forcing asset sales or dilutive financing, supporting stability through revenue cycles.
CDMO Expansion & U.S. FootprintSteady CDMO growth and the Phoenix integration create durable structural revenue optionality: sterile fill‑finish scale, a U.S. footprint and new filling capacity support longer-term contract wins, customer diversification and higher-margin service revenue that can reduce cyclicality tied to proprietary drug sales.
Proprietary Product Uptake (Okedi)Rapid Okedi adoption demonstrates durable commercial traction and product differentiation. As a growing proprietary franchise, Okedi diversifies revenue away from heparin cyclical exposure, supports higher gross margins, and provides a scalable marketing and distribution platform to commercialize future launches.
Bears Say
Sharp Revenue DeteriorationA large decline in trailing revenues weakens operating leverage and reduces internal funding for R&D and capacity projects. Sustained top-line contraction can pressure margins, delay investment paybacks and make long-term targets (e.g., CDMO scale) harder to achieve without material market-share recovery or new contract wins.
Heparin Concentration & Pricing PressureHigh dependence on heparin (≈40% of revenues) exposes ROVI to structural pricing pressure and competitive supply dynamics. Continued volume and price declines reduce scale economics, increase revenue volatility and complicate forecasting, undermining the stability of profitability until diversification succeeds.
Rising Operating Costs And Elevated R&DMaterial increases in SG&A and R&D raise the firm's structural cost base and cash burn. If revenue recovery lags, higher fixed and investment spending will compress margins and free cash flow conversion, forcing harder trade-offs among growth projects, CDMO investments and shareholder distributions over the medium term.
Laboratorios Farmaceuticos Rovi News
ROVI FAQ
What was Laboratorios Farmaceuticos Rovi, SA’s price range in the past 12 months?
Laboratorios Farmaceuticos Rovi, SA lowest stock price was €50.90 and its highest was €86.70 in the past 12 months.
What is Laboratorios Farmaceuticos Rovi, SA’s market cap?
Laboratorios Farmaceuticos Rovi, SA’s market cap is €2.96B.
When is Laboratorios Farmaceuticos Rovi, SA’s upcoming earnings report date?
Laboratorios Farmaceuticos Rovi, SA’s upcoming earnings report date is Jul 29, 2026 which is in 69 days.
How were Laboratorios Farmaceuticos Rovi, SA’s earnings last quarter?
Laboratorios Farmaceuticos Rovi, SA released its earnings results on May 06, 2026. The company reported €0.185 earnings per share for the quarter, beating the consensus estimate of N/A by €0.185.
Is Laboratorios Farmaceuticos Rovi, SA overvalued?
According to Wall Street analysts Laboratorios Farmaceuticos Rovi, SA’s price is currently Undervalued.
Does Laboratorios Farmaceuticos Rovi, SA pay dividends?
Laboratorios Farmaceuticos Rovi, SA pays a Annually dividend of €0.935 which represents an annual dividend yield of 1.5%. See more information on Laboratorios Farmaceuticos Rovi, SA dividends here
What is Laboratorios Farmaceuticos Rovi, SA’s EPS estimate?
Laboratorios Farmaceuticos Rovi, SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Laboratorios Farmaceuticos Rovi, SA have?
Laboratorios Farmaceuticos Rovi, SA has 51,235,764 shares outstanding.
What happened to Laboratorios Farmaceuticos Rovi, SA’s price movement after its last earnings report?
Laboratorios Farmaceuticos Rovi, SA reported an EPS of €0.185 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -16.02%.
Which hedge fund is a major shareholder of Laboratorios Farmaceuticos Rovi, SA?
Currently, no hedge funds are holding shares in ES:ROVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Laboratorios Farmaceuticos Rovi Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.50%
12-Months-Change
Fundamentals
Return on Equity
20.89%
Trailing 12-Months
Asset Growth
13.80%
Trailing 12-Months
Company Description
Laboratorios Farmaceuticos Rovi, SA
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and Medicebrán to treat attention deficit hyperactivity disorder in children and teenagers. The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT Exprès that are contrast injection systems and compatible disposable material. It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves wholesalers, doctors, nursing staff, pharmacists, and patients. It has a collaboration with Moderna, Inc. for manufacturing mRNA COVID-19 vaccine candidate. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
ROVI Stock 12 Month Forecast
Average Price Target
€73.60
▲(13.41% Upside)
Technical Analysis
Options Prices
Currently, No data available
---